| Scorecard |
|---|
|
2 / 5 Stars
|
|
Lipper
3
3
5
3
3
|
|
Zacks Investment Research
4
(Sell)
|
|
Standard & Poor's
3 / 5 Stars
|
|
TheStreet.com
A-
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 2.3 | 2.3 |
| Stocks | 66.96 | 66.96 |
| Bonds | 0.0 | 0.0 |
| Other | 0.0 | 0.0 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 30.74 | 30.74 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 12.31.2012
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 12.31.2012
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Pfizer Inc | PFE | 16.19 | 4.79 |
| Roche Holding AG | RHHVF | 23.65 | 4.65 |
| Novartis AG ADR | NVS | 18.86 | 4.26 |
| Johnson & Johnson | JNJ | 21.03 | 4.2 |
| Abbott Laboratories | ABT | 18.6 | 3.84 |
| Gilead Sciences Inc | GILD | 36.53 | 3.29 |
| Sanofi ADR | SNY | 11.59 | 3.05 |
| Bayer AG | BAYN | --- | 2.79 |
| Shire PLC ADR | SHPG | 1.76 | 2.57 |
| McKesson, Inc. | MCK | 9.27 | 2.51 |
